- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Chart
Detailed Quote
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.
Top 3 Medical Device ETFs for Investors in 2026
How to Invest in Gene Stocks and ETFs
5 Genetic Testing Stocks
Alert Options
You will be notified when this event occurs. No additional settings needed.


